...
首页> 外文期刊>International immunopharmacology >Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice
【24h】

Nasal vaccination with pneumococcal surface protein A in combination with cationic liposomes consisting of DOTAP and DC-chol confers antigen-mediated protective immunity against Streptococcus pneumoniae infections in mice

机译:鼻腔接种肺炎球菌表面蛋白A与阳离子脂质体组合,由DOTAP和DC-CHOL组合赋予抗原介导的小鼠肺炎链球菌感染的抗原介导的保护免疫力

获取原文
获取原文并翻译 | 示例
   

获取外文期刊封面封底 >>

       

摘要

Infectious diseases are the second leading cause of death worldwide, suggesting that there is still a need for the development of new and improved strategies for combating pathogens effectively. Streptococcus pneumoniae is the most virulent bacteria causing pneumonia with high mortality, especially in children and the elderly. Because of the emergence of antibiotic resistance in S. pneumoniae, employing a serotype-independent mucosal vaccine would be the best approach to prevent and treat the diseases caused by S. pneumoniae. In this study, we have developed a pneumococcal nasal vaccine, consisting of pneumococcal surface protein A (PspA) and cationic liposomes composed of 1,2-dioleoyl-3-trimethylammonium-propane (DOTAP) and cholesteryl 313-N(dimethylaminoethypcarbamate (DC-chol) (DOTAP/DC-chol liposome). The efficiency of this cationic liposomebased PspA nasal vaccine was examined in a murine model of S. pneumoniae infection. Intranasal vaccination with PspA and DOTAP/DC-chol liposomes conferred protective immunity against lethal inhalation of S. pneumoniae, improving the survival rate of infected mice. Moreover, intranasal immunization with PspA and DOTAP/ DC-chol liposomes not only induced the production of PspA-specific IgA and IgG by both mucosal and systemic compartments but also elicited PspA-specific Th17 responses, which play a pivotal role in controlling S. pneumoniae infection by host innate immune response. We further demonstrated that DOTAP/DC-chol liposomes enhanced PspA uptake by nasal dendritic cells (DCs), which might be a mechanism for the induction of protective immune responses to S. pneumoniae infection. These results show that DOTAP/DC-chol liposome would be an efficient mucosal vaccine system for a serotype-independent universal nasal vaccine against pneumococcal infection.
机译:传染病是全世界死亡的第二个主要原因,这表明仍然需要开发新的和改进对抗病原体的策略。肺炎链球菌是最致力的细菌,导致肺炎的死亡率高,特别是在儿童和老年人。由于S.肺炎的抗生素抗性的出现,使用血清型无粘膜疫苗是预防和治疗S.肺炎造成的疾病的最佳方法。在这项研究中,我们开发了一种肺炎球菌鼻腔疫苗,由肺炎球菌表面蛋白A(PSPA)和阳离子脂质体组成,由1,2-二脲-3-三甲基三甲基丙烷(DOTAP)和胆甾醇313-N(二甲基氨基甲烷酸酯(DC- CHOL)(DOTAP / DC-CHOL脂质体)。在S.肺炎肺炎感染的小鼠模型中检测了这种阳离子脂质化合物的PSPA鼻疫苗的效率。用PSPA和DOTAP / DC-CHOL脂质体的鼻内接种赋予了致死吸入的保护性免疫力S.肺炎,提高受感染小鼠的存活率。此外,用PSPA和DOTAP / DC-CHOL脂质体的鼻内免疫不仅诱导了粘膜和全身隔间的PSPA特异性IgA和IgG,还引起了PSPA特异性Th17反应,在通过宿主先天免疫应答控制S.肺炎肺炎感染方面发挥着关键作用。我们进一步证明DotAP / DC-CHOL脂质体增强了鼻塞的PSPA吸收TiC细胞(DCS),这可能是对肺炎肺炎感染的保护性免疫反应诱导的机制。这些结果表明,DOTAP / DC-CHOL脂质体将是血清型通用鼻疫苗的有效粘膜疫苗系统,抗肺炎球菌感染。

著录项

相似文献

  • 外文文献
  • 中文文献
  • 专利
获取原文

客服邮箱:kefu@zhangqiaokeyan.com

京公网安备:11010802029741号 ICP备案号:京ICP备15016152号-6 六维联合信息科技 (北京) 有限公司©版权所有
  • 客服微信

  • 服务号